The iAUC INR appeared unaffected by semaglutide coadministration, with a ratio of 1.00 (90% CI 0.931.06)
Some patients report that musculoskeletal discomfort tends to peak during the initial titration phase or periods of rapid weight loss, then gradually diminishes over subsequent weeks to months, though this observation is largely anecdotal and not well-documented in clinical studies
Consistent with previous research, SES also emerged as a key variable, with individuals in medium-SES regions showing an elevated risk than those in high-SES areas
In clinical trials, the incidence was approximately 0.23% (3 out of 1,306 participants)
Theres still ample time for you to pursue legal action if youve experienced health issues after using semaglutide
Read clinical review Clinician-reviewed guide to switching between Zepbound (tirzepatide) and Trulicity (dulaglutide), covering dose mapping, washout timing, side effects, and what the trial data says about efficacy differences